B+
Bull case
25%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
OMER
OmerosBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-10
Recent news sentiment (30D)
+0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+74.6
Score
AI commentary
Headline tone is constructive after Q2 YARTEMLEA sales, CMS support, and capital-structure actions, but the EMA setback offsets part of the upside. The packet includes a secondary headline reporting a sharp after-hours gain, but trusted post-release price follow-through is unavailable. Analyst revisions, target changes, options data, short interest, and employee sentiment are unavailable; this remains a low-coverage monitoring setup rather than a high-conviction bullish call.
RankAlpha Sentiment Codex - 2026-09-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-01eventYARTEMLEA CMS NTAP reimbursementHigh impact
CMS granted YARTEMLEA New Technology Add-on Payment status effective October 1, 2026, supporting eligible hospital reimbursement and patient access. [#SEC-8K-2026-08-12]
2026-12-09eventEMA narsoplimab re-examinationHigh impact
The EMA adopted a negative opinion on narsoplimab in TA-TMA, and Omeros requested re-examination with external expert review. A favorable outcome could expand European opportunity, while delay or rejection remains a material downside risk. [#SEC-8K-2026-08-12]
2026-12-09catalystYARTEMLEA commercial ramp and cash conversionHigh impact
Q2 gross YARTEMLEA revenue reached $32.2 million, up 190% quarter over quarter; net revenue was $28.5 million and operating cash flow was $4.1 million. Adjusted net income was $1.8 million, while GAAP income benefited from non-cash derivative gains. The results were reported in Omeros's investor release furnished with [#SEC-8K-2026-08-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-10 • Updated nightlySource: Internal modelMethodology